77 results
8-K
EX-99.1
TRML
Tourmaline Bio Inc
13 May 24
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
7:15am
release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation … in the regulatory environment; the uncertainties and timing of the regulatory approval process; unexpected litigation or other disputes; the impacts
8-K
EX-99.1
TRML
Tourmaline Bio Inc
19 Mar 24
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
7:09am
not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995 … process; unexpected litigation or other disputes; the impacts of macroeconomic conditions Tourmaline’s business, clinical trials and financial position
8-K
EX-1.1
TRML
Tourmaline Bio Inc
26 Jan 24
Other Events
4:12pm
in settlement of any litigation, if such settlement is effected with the written consent of the Company), insofar as such loss, claim, damage, liability … of any litigation, if such settlement is effected with the written consent of such Underwriter), insofar as such loss, claim, damage, liability or expense
8-K
l2afkt0z
26 Jan 24
Other Events
4:12pm
8-K
EX-99.1
viu ijmx0
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
EX-99.1
3vtmfl
8 Jan 24
Regulation FD Disclosure
9:19am
8-K
EX-99.2
7euzn4 984
8 Jan 24
Regulation FD Disclosure
9:19am
8-K
miu nko8d
8 Jan 24
Regulation FD Disclosure
9:19am
8-K
EX-99.1
nkktt236npnvml9wiefx
14 Dec 23
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
8:27am
8-K
EX-99.1
39f3wa 654
14 Nov 23
Index to Unaudited Condensed Financial Statements
5:15pm
8-K
EX-99.1
0g637n
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
acwxuc ev
17 Oct 23
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
6:35pm
8-K
EX-99.1
sgvj40mda7grflapmn
17 Oct 23
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
6:35pm
425
o0oxozor7hg44 abl
10 Oct 23
Business combination disclosure
4:32pm
8-K/A
nfr0pyhq 16
10 Oct 23
Other Events
4:30pm
425
rdb04
10 Oct 23
Business combination disclosure
12:00am
8-K
mttmq 54q2
6 Oct 23
Talaris Therapeutics Declares Special Dividend
5:30pm